Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MPI | P34949 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromomethane SCHEMBL7011845 | 0.87 | SLC6A3 (0.50) | SLC6A3SLC6A4SLC6A2ALDH1A1MEN1 | |
| SCHEMBL29389473 | 0.87 | BCAT2 (0.52) | SLC6A3SLC6A4SLC6A2ALDH1A1MEN1 | |
| SCHEMBL9531321 | 0.87 | BCAT2 (0.52) | SLC6A3SLC6A4SLC6A2ALDH1A1MEN1 | |
| SCHEMBL517 | 0.86 | SLC6A3 (0.50) | SLC6A3SLC6A4SLC6A2ACHEALDH1A1 | |
| SCHEMBL1665535 | 0.85 | SLC6A3 (0.49) | SLC6A3SLC6A4SLC6A2ACHEALDH1A1 | |
| SCHEMBL9373323 | 0.84 | SLC6A3 (0.49) | SLC6A3SLC6A4SLC6A2ACHEMEN1 | |
| Methylamine SCHEMBL28010440 | 0.84 | BCAT2 (0.53) | SLC6A3SLC6A4SLC6A2ALDH1A1MEN1 | |
| SCHEMBL5698693 | 0.84 | SLC6A3 (0.48) | SLC6A3SLC6A4SLC6A2ACHERAB9A | |
| SCHEMBL283 | 0.84 | SLC6A3 (0.48) | SLC6A3SLC6A4SLC6A2ACHEALDH1A1 | |
| SCHEMBL6900070 | 0.83 | SLC6A3 (0.48) | SLC6A3SLC6A4SLC6A2ACHERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216970-B2 | Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-20150105392-A1 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-04-16 | — | — | US | disclosed |
| US-8946233-B2 | Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140135333-A1 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8664227-B2 | Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents | THERAVANCE, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130267539-A1 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-8481549-B2 | Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents | THERAVANCE, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20110178101-A1 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178101-A1 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS | REN, AGTR1, AGTR2 | SLC6A3 372/4885SLC6A4 248/4885SLC6A2 343/4885 |
| US-20140135333-A1 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS | REN, AGTR1, AGTR2 | SLC6A3 372/4885SLC6A4 248/4885SLC6A2 343/4885 |
| US-20130267539-A1 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS | REN, AGTR1, AGTR2 | SLC6A3 372/4885SLC6A4 248/4885SLC6A2 343/4885 |
| US-20150105392-A1 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS | REN, AGTR1, AGTR2 | SLC6A3 372/4885SLC6A4 248/4885SLC6A2 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.